Page 10 - Athersys Inc News Today

/PRNewswire/ -- The hematopoietic stem cells transplantation (HSCT) market size is set to grow by USD 2383.61 million between 2023 and 2027, and register a...

The soft tissue repair market refers to the medical devices and treatments used to repair or replace damaged or injured soft tissues in the body, such as tendons, ligaments, muscles, and cartilage. This can include both surgical and non-surgical interventions, such as physical therapy and regenerative medicine.Soft...

Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced today its participation in three upcoming conferences during the... | May 8, 2023

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be par...

StockNews.com upgraded shares of Athersys (NASDAQ:ATHX – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday morning. Separately, Alliance Global Partners began coverage on shares of Athersys in a report on Monday, March 6th. They set a buy rating and a $5.50 target price on the […]

StockNews.com upgraded shares of Athersys (NASDAQ:ATHX – Get Rating) from a sell rating to a hold rating in a report published on Tuesday. Separately, Alliance Global Partners began coverage on shares of Athersys in a research note on Monday, March 6th. They issued a buy rating and a $5.50 price objective on the stock. Athersys […]

Stock Analysts’ upgrades for Tuesday, May 2nd: Athersys (NASDAQ:ATHX) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. Franklin Resources (NYSE:BEN) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. Conn’s (NASDAQ:CONN) was upgraded by analysts at StockNews.com from a sell rating to a hold […]

Athersys (NASDAQ:ATHX – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. Separately, Alliance Global Partners initiated coverage on Athersys in a report on Monday, March 6th. They set a “buy” rating and a $5.50 target price on the stock. Athersys Trading Down […]

Athersys, Inc. (NASDAQ:ATHX – Get Rating) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,130,000 shares, a decrease of 9.6% from the March 31st total of 1,250,000 shares. Based on an average daily volume of 243,600 shares, the days-to-cover […]

Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and... | May 1, 2023